Megan S. Farris
Research Subjects
Megan S. Farris has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jean Addington
Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
7 shared publications Glenda MacQueen
Department of Psychiatry, Hotchkiss Brain Institute University of Calgary Calgary Alberta Canada
3 shared publications- Amy Braun
Department of Psychiatry Hotchkiss Brain Institute, University of Calgary Calgary Alberta Canada
2 shared publications Benjamin I. Goldstein
Centre for Youth Bipolar Disorder Sunnybrook Health Sciences Centre Toronto Ontario Canada
2 shared publications- Bryan Har
University of Calgary
2 shared publications Catherine Lebel
Department of Radiology University of Calgary Calgary Alberta Canada
2 shared publications
Latest Publications
- Open Access
- 15 March 2023
- Published by Springer Nature in Cardiology and Therapy
- Vol. 12 (2) , 339
Correction to: Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
- 15 March 2023
- Published by Springer Nature in Cardiology and Therapy
- Vol. 12 (2) , 339
Open AccessCorrection to: Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
- Open Access
- 19 January 2023
- Published by Springer Nature in Cardiology and Therapy
- Vol. 12 (2) , 327-338
Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
Introduction A high proportion of Canadian patients with acute myocardial infarction (AMI) do not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended by the Canadian Cardiovascular Society in 2021. This increases the risk of subsequent atherosclerotic cardiovascular disease (ASCVD) events. Here, we assess LDL-C levels and threshold achievement among patients by lipid-lowering therapies (LLT) received post-AMI. Methods A retrospective cohort study of patients identified with AMI between 2015 and 2019 was conducted using administrative health databases in Alberta, Canada. Patients were grouped by their highest-intensity LLT post-AMI (proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) + another LLT; PCSK9i alone; ezetimibe + statin; statins (high, moderate, low intensity); or ezetimibe alone), and available LDL-C levels were examined in the year before and after LLT dispense date. Results The cohort included 15,283 patients. In patients on PCSK9i + LLT, the median [95% confidence interval (CI)] LDL-C levels decreased from 2.7 (2.3–3.4) before to 0.9 (0.5–1.2) mmol/l after treatment, the largest decrease among treatment groups. In the ezetimibe + statin and high-intensity statin groups, median (95% CI) values after treatment were 1.5 (1.5–1.6) and 1.4 (1.4–1.4) mmol/l, respectively. The proportion of patients below the 1.8 mmol/l threshold increased by 77.7% in the PSCK9i + LLT group after treatment, compared to 45.4 and 32.4% in the ezetimibe + statin and high-intensity statin groups, respectively. Conclusions Intensification with PCSK9i in AMI patients results in a greater proportion of patients achieving below the recommended LDL-C threshold versus statins and or ezetimibe alone. Increased focus on achieving below the LDL-C thresholds with additional LLT as required may benefit patient cardiovascular outcomes.
- 19 January 2023
- Published by Springer Nature in Cardiology and Therapy
- Vol. 12 (2) , 327-338
Open AccessGuideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
Introduction A high proportion of Canadian patients with acute myocardial infarction (AMI) do not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended by the Canadian Cardiovascular Society in 2021. This increases the risk of subsequent atherosclerotic cardiovascular disease (ASCVD) events. Here, we assess LDL-C levels and threshold achievement among patients by lipid-lowering therapies (LLT) received post-AMI. Methods A retrospective cohort study of patients identified with AMI between 2015 and 2019 was conducted using administrative health databases in Alberta, Canada. Patients were grouped by their highest-intensity LLT post-AMI (proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) + another LLT; PCSK9i alone; ezetimibe + statin; statins (high, moderate, low intensity); or ezetimibe alone), and available LDL-C levels were examined in the year before and after LLT dispense date. Results The cohort included 15,283 patients. In patients on PCSK9i + LLT, the median [95% confidence interval (CI)] LDL-C levels decreased from 2.7 (2.3–3.4) before to 0.9 (0.5–1.2) mmol/l after treatment, the largest decrease among treatment groups. In the ezetimibe + statin and high-intensity statin groups, median (95% CI) values after treatment were 1.5 (1.5–1.6) and 1.4 (1.4–1.4) mmol/l, respectively. The proportion of patients below the 1.8 mmol/l threshold increased by 77.7% in the PSCK9i + LLT group after treatment, compared to 45.4 and 32.4% in the ezetimibe + statin and high-intensity statin groups, respectively. Conclusions Intensification with PCSK9i in AMI patients results in a greater proportion of patients achieving below the recommended LDL-C threshold versus statins and or ezetimibe alone. Increased focus on achieving below the LDL-C thresholds with additional LLT as required may benefit patient cardiovascular outcomes.
- 13 February 2022
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 16 (11) , 1211-1216
Longitudinal impact of trauma in the North American Prodrome Longitudinal Study‐3
Aim Individuals at clinical high risk (CHR) for psychosis have been shown to experience more trauma than the general population. However, although the effects of trauma appear to impact some symptoms it does not seem to increase the risk of transition to psychosis. The aim of this article was to examine the prevalence of trauma, and its association with longitudinal clinical and functional outcomes in a large sample of CHR individuals. Methods From the North American Prodrome Longitudinal Study-3 (NAPLS-3) 690 CHR individuals and 91 healthy controls from nine study sites between 2015 and 2018 were assessed. Historical trauma experiences were captured at baseline. Participants completed longitudinal assessments measuring clinical outcomes including positive and negative symptoms, depression, social and role functioning and assessing transition to psychosis. Results From the 690 CHR participants and 96 healthy controls, 343 (49.6%) and 15 (15.6%), respectively, reported a history of trauma (p < .001). Emotional neglect (70.3%) was the most commonly reported type of trauma, followed by psychological abuse (57.4%). Among CHR participants, time to transition to psychosis was not associated with trauma. Baseline depression and suspiciousness/persecutory ideas were statistically significantly different between CHR individuals who did or did not experience trauma. However, when examining clinical and functional outcomes over 12-months of follow-up, there were no differences between those who experienced trauma and those who did not. Conclusion Overall, trauma is a significantly prevalent among CHR individuals. The effects of trauma on transition and longitudinal clinical and functional outcomes were not significant.
- 13 February 2022
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 16 (11) , 1211-1216
Longitudinal impact of trauma in the North American Prodrome Longitudinal Study‐3
Aim Individuals at clinical high risk (CHR) for psychosis have been shown to experience more trauma than the general population. However, although the effects of trauma appear to impact some symptoms it does not seem to increase the risk of transition to psychosis. The aim of this article was to examine the prevalence of trauma, and its association with longitudinal clinical and functional outcomes in a large sample of CHR individuals. Methods From the North American Prodrome Longitudinal Study-3 (NAPLS-3) 690 CHR individuals and 91 healthy controls from nine study sites between 2015 and 2018 were assessed. Historical trauma experiences were captured at baseline. Participants completed longitudinal assessments measuring clinical outcomes including positive and negative symptoms, depression, social and role functioning and assessing transition to psychosis. Results From the 690 CHR participants and 96 healthy controls, 343 (49.6%) and 15 (15.6%), respectively, reported a history of trauma (p < .001). Emotional neglect (70.3%) was the most commonly reported type of trauma, followed by psychological abuse (57.4%). Among CHR participants, time to transition to psychosis was not associated with trauma. Baseline depression and suspiciousness/persecutory ideas were statistically significantly different between CHR individuals who did or did not experience trauma. However, when examining clinical and functional outcomes over 12-months of follow-up, there were no differences between those who experienced trauma and those who did not. Conclusion Overall, trauma is a significantly prevalent among CHR individuals. The effects of trauma on transition and longitudinal clinical and functional outcomes were not significant.
- Open Access
- 29 September 2021
- Published by Wiley in Clinical Cardiology
- Vol. 44 (11) , 1613-1620
Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real‐world evidence study
Background: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Data from Canadian populations regarding the burden of ASCVD are limited. Therefore, we describe the 5‐year period prevalence of ASCVD and subsequent major adverse cardiovascular event (MACE) outcomes among patients with ASCVD in Alberta, Canada.Methods: A retrospective, observational study was conducted by linking provincial health services data, vital statistics, and pharmaceutical dispenses data. Five‐year period prevalence of clinical ASCVD was captured between 2011 and 2016, and a cohort of adult patients with an initial clinical ASCVD event were identified between 2012 and 2016. One‐year incidence rates (IRs) of subsequent MACE outcomes were calculated as composite and individual measures. A subgroup of patients with acute myocardial infarction (AMI) as their index event was examined.Results: There were 198 573 patients (mean [standard deviation] age: 63.9 [15.6] years; 56.6% males) identified with clinical ASCVD between 2012 and 2016. Overall, the 5‐year period prevalence of ASCVD in Alberta was 89.9 per 1000 persons and the 1‐year IR for a primary MACE outcome was 6.15 (95% confidence interval [CI]: 6.03–6.26) per 100 person‐years. Among the ASCVD cohort, 9465 had an AMI as their index event and the IR for a primary MACE outcome was 14.30 (95% CI: 13.45–15.20) per 100 person‐years.Conclusions: This study found that the prevalence of ASCVD and the rate of subsequent MACE outcomes 1 year following the initial ASCVD event are substantial, particularly among patients with an AMI. Secondary prevention strategies aimed at lowering this risk are needed for patients with ASCVD.
- 29 September 2021
- Published by Wiley in Clinical Cardiology
- Vol. 44 (11) , 1613-1620
Open AccessPrevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real‐world evidence study
Background: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Data from Canadian populations regarding the burden of ASCVD are limited. Therefore, we describe the 5‐year period prevalence of ASCVD and subsequent major adverse cardiovascular event (MACE) outcomes among patients with ASCVD in Alberta, Canada.Methods: A retrospective, observational study was conducted by linking provincial health services data, vital statistics, and pharmaceutical dispenses data. Five‐year period prevalence of clinical ASCVD was captured between 2011 and 2016, and a cohort of adult patients with an initial clinical ASCVD event were identified between 2012 and 2016. One‐year incidence rates (IRs) of subsequent MACE outcomes were calculated as composite and individual measures. A subgroup of patients with acute myocardial infarction (AMI) as their index event was examined.Results: There were 198 573 patients (mean [standard deviation] age: 63.9 [15.6] years; 56.6% males) identified with clinical ASCVD between 2012 and 2016. Overall, the 5‐year period prevalence of ASCVD in Alberta was 89.9 per 1000 persons and the 1‐year IR for a primary MACE outcome was 6.15 (95% confidence interval [CI]: 6.03–6.26) per 100 person‐years. Among the ASCVD cohort, 9465 had an AMI as their index event and the IR for a primary MACE outcome was 14.30 (95% CI: 13.45–15.20) per 100 person‐years.Conclusions: This study found that the prevalence of ASCVD and the rate of subsequent MACE outcomes 1 year following the initial ASCVD event are substantial, particularly among patients with an AMI. Secondary prevention strategies aimed at lowering this risk are needed for patients with ASCVD.
- Open Access
- 19 January 2021
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 66 (4) , 418-420
Longitudinal Trends in Medication Treatment for Youth At-Risk for Serious Mental Illness
- 19 January 2021
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 66 (4) , 418-420
Open AccessLongitudinal Trends in Medication Treatment for Youth At-Risk for Serious Mental Illness
- 9 October 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (5) , 1188-1196
Clinical staging for youth at‐risk for serious mental illness: A longitudinal perspective
Objective: The objective of this study was to identify a sample of youth in distinct stages of risk for the development of a serious mental illness (SMI) according to a published clinical staging model and to follow this sample longitudinally to determine clinical changes over time. This article reports the 6‐ and 12‐month follow‐up of the cohort.Methods: This study recruited 243 youth, ages 12 to 25. The sample included (a) 42 healthy controls, (b) 41 nonhelpseeking individuals with no mental illness but some risk of SMI, for example, having a first‐degree relative with an SMI (stage 0), (c) 53 youth experiencing distress and mild symptoms of anxiety or depression (stage 1a), and (d) 107 youth with attenuated symptoms of SMIs such as bipolar disorder or psychosis (stage 1b). Participants completed a range of measures assessing depression, anxiety, mania, suicide ideation, attenuated psychotic symptoms, negative symptoms, anhedonia and beliefs about oneself at baseline, 6‐ and 12‐months.Results: There were few changes for healthy controls and stage 0 participants, although approximately 7% did move to a symptomatic stage within 12‐months. Of stage 1a participants, 50% remained symptomatic, with 7.5% moving to stage 1b or developing a SMI. Approximately 9% of stage 1byouth developed a SMI within 12‐months and approximately one‐third had remission of symptoms during the follow‐up.Conclusions: Results suggest that the implementation of a transdiagnostic staging model may be useful in youth mental health and support consideration of clinical stage‐based treatment for youth with early features of risk.
- 9 October 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (5) , 1188-1196
Clinical staging for youth at‐risk for serious mental illness: A longitudinal perspective
Objective: The objective of this study was to identify a sample of youth in distinct stages of risk for the development of a serious mental illness (SMI) according to a published clinical staging model and to follow this sample longitudinally to determine clinical changes over time. This article reports the 6‐ and 12‐month follow‐up of the cohort.Methods: This study recruited 243 youth, ages 12 to 25. The sample included (a) 42 healthy controls, (b) 41 nonhelpseeking individuals with no mental illness but some risk of SMI, for example, having a first‐degree relative with an SMI (stage 0), (c) 53 youth experiencing distress and mild symptoms of anxiety or depression (stage 1a), and (d) 107 youth with attenuated symptoms of SMIs such as bipolar disorder or psychosis (stage 1b). Participants completed a range of measures assessing depression, anxiety, mania, suicide ideation, attenuated psychotic symptoms, negative symptoms, anhedonia and beliefs about oneself at baseline, 6‐ and 12‐months.Results: There were few changes for healthy controls and stage 0 participants, although approximately 7% did move to a symptomatic stage within 12‐months. Of stage 1a participants, 50% remained symptomatic, with 7.5% moving to stage 1b or developing a SMI. Approximately 9% of stage 1byouth developed a SMI within 12‐months and approximately one‐third had remission of symptoms during the follow‐up.Conclusions: Results suggest that the implementation of a transdiagnostic staging model may be useful in youth mental health and support consideration of clinical stage‐based treatment for youth with early features of risk.
- 4 June 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (3) , 634-641
Substance use in youth at‐risk for serious mental illness
Aim The aim of this paper is to describe the substance use of participants who are at‐risk for serious mental illness (SMI). Method The Canadian Psychiatric Risk and Outcome study (PROCAN) is a two‐site study of 243 youth and young adults aged 13 to 25 years, categorized into four groups: healthy controls (n = 42), stage 0 (asymptomatic individuals with risk of SMI typically family high risk; n = 41), stage 1a (distress disorder or mild symptoms of anxiety or depression; n = 53) and stage 1b (attenuated syndromes, including bipolar disorder or psychosis; n = 107). Substance use measures were administered at baseline, 6‐ and 12‐months. Results At baseline, the most commonly reported substance used in the past month was alcohol (43.6%), followed by cannabis (14.4%) and tobacco (12.4%). There were no significant group differences in use. 42.4% of all participants reported ever using cannabis in their lifetime, whereas 21.4% reported currently using cannabis. There were no group differences in ever having used cannabis. Regarding lifetime substance abuse disorders, cannabis use disorder (5.7%) and alcohol use disorder (4.5%) were the most common and more often reported in stage 1b participants relative to other groups. Furthermore, alcohol, cannabis and tobacco use remained relatively consistent at 6‐ and 12‐month follow‐ups when compared to baseline use. Conclusion Alcohol was the most commonly used substance followed by cannabis and tobacco. Although substance use did not differ between those at different stages of risk, overall prevention strategies are still warranted for youth at‐risk for SMI, especially those who are more symptomatic and potentially at greater risk of developing an SMI.
- 4 June 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (3) , 634-641
Substance use in youth at‐risk for serious mental illness
Aim The aim of this paper is to describe the substance use of participants who are at‐risk for serious mental illness (SMI). Method The Canadian Psychiatric Risk and Outcome study (PROCAN) is a two‐site study of 243 youth and young adults aged 13 to 25 years, categorized into four groups: healthy controls (n = 42), stage 0 (asymptomatic individuals with risk of SMI typically family high risk; n = 41), stage 1a (distress disorder or mild symptoms of anxiety or depression; n = 53) and stage 1b (attenuated syndromes, including bipolar disorder or psychosis; n = 107). Substance use measures were administered at baseline, 6‐ and 12‐months. Results At baseline, the most commonly reported substance used in the past month was alcohol (43.6%), followed by cannabis (14.4%) and tobacco (12.4%). There were no significant group differences in use. 42.4% of all participants reported ever using cannabis in their lifetime, whereas 21.4% reported currently using cannabis. There were no group differences in ever having used cannabis. Regarding lifetime substance abuse disorders, cannabis use disorder (5.7%) and alcohol use disorder (4.5%) were the most common and more often reported in stage 1b participants relative to other groups. Furthermore, alcohol, cannabis and tobacco use remained relatively consistent at 6‐ and 12‐month follow‐ups when compared to baseline use. Conclusion Alcohol was the most commonly used substance followed by cannabis and tobacco. Although substance use did not differ between those at different stages of risk, overall prevention strategies are still warranted for youth at‐risk for SMI, especially those who are more symptomatic and potentially at greater risk of developing an SMI.
- 26 May 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (3) , 547-553
Pilot aerobic exercise intervention for youth at‐risk for serious mental illness
Background: This study was conducted as a pilot exercise intervention in youth at‐risk for serious mental illness (SMI). The objectives were to examine the feasibility of an exercise intervention and to determine what improvement was observed, following participation in a moderate‐ to high‐intensity aerobic exercise programme.Methods: Forty‐four male and female youth at‐risk for SMI were recruited. Participants completed clinical, lifestyle and fitness assessments prior to and following a 16‐week moderate‐ to high‐intensity aerobic exercise intervention. Sixty‐minute exercise sessions were held three times per week.Results: Forty‐one participants completed the entire intervention and assessments; thus, the retention rate was 93.2%. Exercise participants achieved a mean of 98.3 (standard deviation (SD) 26.1) minutes/week of high‐intensity and a mean of 32.8 (SD 8.7) minutes/week of moderate‐intensity aerobic exercise over the course of 16 weeks. Improvements in aerobic fitness and body composition as well as reductions in anxiety and depression were observed after the exercise intervention.Conclusion: Aerobic exercise is a feasible and sound intervention strategy in youth at‐risk for SMI. Further research is required to expand upon these initial findings and develop knowledge of the mechanisms, optimum dose and factors that influence the efficacy of exercise.
- 26 May 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (3) , 547-553
Pilot aerobic exercise intervention for youth at‐risk for serious mental illness
Background: This study was conducted as a pilot exercise intervention in youth at‐risk for serious mental illness (SMI). The objectives were to examine the feasibility of an exercise intervention and to determine what improvement was observed, following participation in a moderate‐ to high‐intensity aerobic exercise programme.Methods: Forty‐four male and female youth at‐risk for SMI were recruited. Participants completed clinical, lifestyle and fitness assessments prior to and following a 16‐week moderate‐ to high‐intensity aerobic exercise intervention. Sixty‐minute exercise sessions were held three times per week.Results: Forty‐one participants completed the entire intervention and assessments; thus, the retention rate was 93.2%. Exercise participants achieved a mean of 98.3 (standard deviation (SD) 26.1) minutes/week of high‐intensity and a mean of 32.8 (SD 8.7) minutes/week of moderate‐intensity aerobic exercise over the course of 16 weeks. Improvements in aerobic fitness and body composition as well as reductions in anxiety and depression were observed after the exercise intervention.Conclusion: Aerobic exercise is a feasible and sound intervention strategy in youth at‐risk for SMI. Further research is required to expand upon these initial findings and develop knowledge of the mechanisms, optimum dose and factors that influence the efficacy of exercise.
- 3 December 2019
- Published by Springer Nature in Social Psychiatry and Psychiatric Epidemiology
- Vol. 55 (5) , 527-537
Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review
The objectives of this review were to understand the prevalence of cannabis use and how cannabis is associated with transition to psychosis, symptoms, cognition, trauma and family history in clinical high risk (CHR) for psychosis individuals.
- 3 December 2019
- Published by Springer Nature in Social Psychiatry and Psychiatric Epidemiology
- Vol. 55 (5) , 527-537
Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review
The objectives of this review were to understand the prevalence of cannabis use and how cannabis is associated with transition to psychosis, symptoms, cognition, trauma and family history in clinical high risk (CHR) for psychosis individuals.
- 18 August 2019
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 14 (5) , 515-527
Attrition rates in trials for adolescents and young adults at clinical high‐risk for psychosis: A systematic review and meta‐analysis
Background: Treatment of those at clinical high‐risk (CHR) for developing psychosis may lead to preventive strategies. However, attrition in trials may hamper efforts to detect effective changes and lead to bias. Our objective was to synthesize the relative attrition rates in clinical trials conducted in CHR for psychosis samples.Method: We searched the following electronic databases: MEDLINE, Embase, PsycINFO, CINAHL and EBM with no restrictions. Inclusion criteria was any treatment‐based randomized controlled trial (RCT) conducted in CHR samples that reported attrition. Relative attrition rates were calculated using random‐effects meta‐analysis, stratified by time, and reported as odds ratios (ORs), proportions, and 95% confidence intervals (CIs).Results: Twenty‐one RCTs met our inclusion criteria, including a total of 2260 CHR participants. Attrition rates between all treatment types identified were not statistically different from control treatments at any time‐point. When accessing overall trial attrition, the pooled attrition rate was 29.57% (95% CI = 23.84‐35.63%) with statistically significant heterogeneity (I2 = 88.70%; P < .001). Furthermore, 11 trials had a subsequent follow‐up after the intervention was conducted and the pooled attrition was 33.96% (95% CI = 24.94‐43.59%). When examining predictors of attrition, no statistically significant subgroup differences were observed in attrition rates.Conclusions: Almost one third of CHR participants will not complete participation in an RCT, however no predictors were found to be statistically significantly related to attrition. Methods to account for missing data and attrition are warranted in CHR trials to account for potential biases associated with high attrition rates.
- 18 August 2019
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 14 (5) , 515-527
Attrition rates in trials for adolescents and young adults at clinical high‐risk for psychosis: A systematic review and meta‐analysis
Background: Treatment of those at clinical high‐risk (CHR) for developing psychosis may lead to preventive strategies. However, attrition in trials may hamper efforts to detect effective changes and lead to bias. Our objective was to synthesize the relative attrition rates in clinical trials conducted in CHR for psychosis samples.Method: We searched the following electronic databases: MEDLINE, Embase, PsycINFO, CINAHL and EBM with no restrictions. Inclusion criteria was any treatment‐based randomized controlled trial (RCT) conducted in CHR samples that reported attrition. Relative attrition rates were calculated using random‐effects meta‐analysis, stratified by time, and reported as odds ratios (ORs), proportions, and 95% confidence intervals (CIs).Results: Twenty‐one RCTs met our inclusion criteria, including a total of 2260 CHR participants. Attrition rates between all treatment types identified were not statistically different from control treatments at any time‐point. When accessing overall trial attrition, the pooled attrition rate was 29.57% (95% CI = 23.84‐35.63%) with statistically significant heterogeneity (I2 = 88.70%; P < .001). Furthermore, 11 trials had a subsequent follow‐up after the intervention was conducted and the pooled attrition was 33.96% (95% CI = 24.94‐43.59%). When examining predictors of attrition, no statistically significant subgroup differences were observed in attrition rates.Conclusions: Almost one third of CHR participants will not complete participation in an RCT, however no predictors were found to be statistically significantly related to attrition. Methods to account for missing data and attrition are warranted in CHR trials to account for potential biases associated with high attrition rates.